Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 7 (1), 1090

Diabetes Mellitus and the Risk of Multidrug Resistant Tuberculosis: A Meta-Analysis

Affiliations
Meta-Analysis

Diabetes Mellitus and the Risk of Multidrug Resistant Tuberculosis: A Meta-Analysis

Qianqian Liu et al. Sci Rep.

Abstract

The high prevalence of diabetes mellitus (DM) among multidrug resistant tuberculosis (MDR-TB) patients is a serious cause for concern. We conducted a meta-analysis to determine whether DM is an independent risk factor for MDR-TB. Electronic literature searches of the PubMed, Web of Science and EMBASE databases up to July 12, 2016 were conducted. The pooled adjusted odds ratio (OR) and 95% confidence intervals (CIs) were calculated using the random effects model with STATA 12.0 software. In total 13 studies, including 9289 individuals with TB, were included in this meta-analysis. Significant association between DM and MDR-TB (OR = 1.71; 95% CI = 1.32, 2.22) was identified. Subgroup analyses showed that: 1) Pooled OR was 1.25 (95% CI: 0.82-1.91) for cross-sectional studies, and was 2.14 (95% CI: 1.51-3.02) for longitudinal studies; 2) The pooled OR was 1.69 (95% CI:1.09-2.62) for primary MDR-TB, 1.94 (95% CI:1.42-2.65) for any MDR-TB, and 0.85 for secondary MDR-TB (95% CI: 0.29-2.54); 3) DM was significantly associated with MDR-TB in both Caucasian (OR = 2.26, 95% CI: 1.66-3.07) and Asian (OR = 1.40, 95% CI: 1.01-1.95) subgroups. No evidence of publication bias was identified. In conclusion, the pooling analysis indicated that DM was an independent risk factor for MDR-TB, especially for primary MDR-TB.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow diagram of included studies.
Figure 2
Figure 2
Forest plot of odds ratio (OR) assessing the association between diabetes mellitus and multidrug resistance tuberculosis. CI, confidence interval.
Figure 3
Figure 3
Funnel plots for publication bias.

Similar articles

See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles

References

    1. WHO. Global tuberculosis report 2015. Geneva, Switzerland: WHO, 2015. http://www.who.int/tb/publications/global_report/en/ (accessed July 1, 2016).
    1. Narayanan, P. R. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis. The Indian journal of tuberculosis54, 84–90 (2007). - PubMed
    1. Ahuja SD, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS medicine. 2012;9:e1001300. doi: 10.1371/journal.pmed.1001300. - DOI - PMC - PubMed
    1. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158–163. doi: 10.1136/thx.2005.045963. - DOI - PMC - PubMed
    1. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2010;14:382–390. - PubMed

Publication types

Feedback